Showing 1 - 12 of 19 results for "04100"
10 Products
- Product Information Sheet
Catalog #: Lot #: Language Product Name: 04100 All English MethoCult™ H4100 Catalog #: 04100 Lot #: All Language English Product Name: MethoCult™ H4100 - ReferencePetzer AL et al. (FEB 1996) Proceedings of the National Academy of Sciences of the United States of America 93 4 1470--4
Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.
A major goal of experimental and clinical hematology is the identification of mechanisms and conditions that support the expansion of transplantable hematopoietic stem cells. In normal marrow, such cells appear to be identical to (or represent a subset of) a population referred to as long-term-culture-initiating cells (LTC-ICs) so-named because of their ability to produce colony-forming cell (CFC) progeny for textgreater or = 5 weeks when cocultured with stromal fibroblasts. Some expansion of LTC-ICs in vitro has recently been described, but identification of the factors required and whether LTC-IC self-renewal divisions are involved have remained unresolved issues. To address these issues, we examined the maintenance and/or generation of LTC-ICs from single CD34+ CD38- cells cultured for variable periods under different culture conditions. Analysis of the progeny obtained from cultures containing a feeder layer of murine fibroblasts engineered to produce steel factor, interleukin (IL)-3, and granulocyte colony-stimulating factor showed that approximately 20% of the input LTC-ICs (representing approximately 2% of the original CD34+ CD38- cells) executed self-renewal divisions within a 6-week period. Incubation of the same CD34+ CD38- starting populations as single cells in a defined (serum free) liquid medium supplemented with Flt-3 ligand, steel factor, IL-3, IL-6, granulocyte colony-stimulating factor, and nerve growth factor resulted in the proliferation of initial cells to produce clones of from 4 to 1000 cells within 10 days, approximately 40% of which included textgreater or = 1 LTC-IC. In contrast, in similar cultures containing methylcellulose, input LTC-ICs appeared to persist but not divide. Overall the LTC-IC expansion in the liquid cultures was 30-fold in the first 10 days and 50-fold by the end of another 1-3 weeks. Documentation of human LTC-IC self-renewal in vitro and identification of defined conditions that permit their extensive and rapid amplification should facilitate analysis of the molecular mechanisms underlying these processes and their exploitation for a variety of therapeutic applications. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 05100 MyeloCult™ H5100 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 05100 Product Name: MyeloCult™ H5100 Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO - ReferenceFarese AM et al. (JAN 1996) Blood 87 2 581--91
Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia.
The synthetic cytokine (Synthokine) SC-55494 is a high-affinity interleukin-3 (IL-3) receptor ligand that stimulates greater in vitro multilineage hematopoietic activity than native IL-3, while inducing no significant increase in inflammatory activity relative to native IL-3. The aim of this study was to investigate the in vivo hematopoietic response of rhesus monkeys receiving Synthokine after radiation-induced marrow aplasia. Administration schedule and dose of Synthokine were evaluated. All animals were total-body irradiated (TBI) with 700 cGy 60Co gamma radiation on day 0. Beginning on day 1, cohorts of animals (n = 5) received Synthokine subcutaneously (SC) twice daily with 25 micrograms/kg/d or 100 micrograms/kg/d for 23 days or 100 micrograms/kg/d for 14 days. Control animals (n = 9) received human serum albumin SC once daily at 15 micrograms/kg/d for 23 days. Complete blood counts were monitored for 60 days postirradiation and the durations of neutropenia (NEUT; absolute neutrophil count [ANC] textless 500/microL) and thrombocytopenia (THROM; platelet count textless 20,000/microL) were assessed. Synthokine significantly (P textless .05) reduced the duration of THROM versus the HSA-treated animals regardless of dose or protocol length. The most striking reduction was obtained in the animals receiving 100 micrograms/kg/d for 23 days (THROM = 3.5 v 12.5 days in HSA control animals). Although the duration of NEUT was not significantly altered, the depth of the nadir was significantly lessened in all animal cohorts treated with Synthokine regardless of dose versus schedule length. Bone marrow progenitor cell cultures indicated a beneficial effect of Synthokine on the recovery of granulocyte-macrophage colony-forming units that was significantly higher at day 24 post-TBI in both cohorts treated at 25 and 100 micrograms/kg/d for 23 days relative to the control animals. Plasma pharmacokinetic parameters were evaluated in both normal and irradiated animals. Pharmacokinetic analysis performed in irradiated animals after 1 week of treatment suggests an effect of repetitive Synthokine schedule and/or TBI on distribution and/or elimination of Synthokine. These data show that the Synthokine, SC55 94, administered therapeutically post-TBI, significantly enhanced platelet recovery and modulated neutrophil nadir and may be clinically useful in the treatment of the myeloablated host. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO 04437 MethoCult™ Express Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO Catalog #: 04437 Product Name: MethoCult™ Express - ReferenceConneally E et al. (JAN 1996) Blood 87 2 456--64
Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer.
Recombinant retroviruses offer many advantages for the genetic modification of human hematopoietic cells, although their use in clinical protocols has thus far given disappointing results. There is therefore an important need to develop new strategies that will allow effectively transduced primitive hematopoietic target populations to be both rapidly characterized and isolated free of residual nontransduced but biologically equivalent cells. To address this need, we constructed a murine stem cell virus (MSCV)-based retroviral vector containing the 228-bp coding sequence of the murine heat-stable antigen (HSA) and generated helper virus-free amphotropic MSCV-HSA producer cells by transfection of GP-env AM12 packaging cells. Light density and, in some cases, lineage marker-negative (lin-) normal human marrow or mobilized peripheral blood cells preactivated by exposure to interleukin-3 (IL-3), IL-6, and Steel factor in vitro for 48 hours were then infected by cocultivation with these MSCV-HSA producer cells for a further 48 hours in the presence of the same cytokines. Fluorescence-activated cell sorting (FACS) analysis of the cells 24 hours later showed 21% to 41% (mean, 27%) of those that were still CD34+ to have acquired the ability to express HSA. The extent of gene transfer to erythroid and granulopoietic progenitors (burst-forming unit-erythroid and colony-forming unit-granulocyte-macrophage), as assessed by the ability of these cells to form colonies of mature progeny in the presence of normally toxic concentrations of G418, averaged 11% and 12%, respectively, in 6 experiments. These values could be increased to 100% and 77%, respectively, by prior isolation of the CD34+HSA+ cell fraction and were correspondingly decreased to an average of 2% and 5%, respectively, in the CD34+HSA- cells. In addition, the extent of gene transfer to long-term culture-initiating cells (LTC-IC) was assessed by G418 resistance. The average gene transfer to LTC-IC-derived colony-forming cells in the unsorted population was textless or = 7% in 4 experiments. FACS selection of the initially CD34+HSA+ cells increased this value to 86% and decreased it to 3% for the LTC-IC plated from the CD34+HSA- cells. Transfer of HSA gene expression to a phenotypically defined more primitive subpopulation of CD34+ cells, ie, those expressing little or no CD38, could also be shown by FACS analysis of infected populations 24 hours after infection. These findings underscore the potential use of retroviral vectors encoding HSA for the specific identification and non-toxic selection immediately after infection of retrovirally transduced populations of primitive human hematopoietic cells. In addition, such vectors should facilitate the subsequent tracking of their marked progeny using multiparameter flow cytometry. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO 04437 MethoCult™ Express Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO Catalog #: 04437 Product Name: MethoCult™ Express - ReferenceMayani H et al. (JUN 1993) Blood 81 12 3252--8
Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells.
To study the role of different cytokine combinations on the proliferation and differentiation of highly purified primitive progenitor cells, a serum-free liquid culture system was used in combination with phenotypic and functional analysis of the cells produced in culture. CD34+ CD45RAlo CD71lo cells, purified from umbilical cord blood by flow cytometry and cell sorting, were selected for this study because of their high content of clonogenic cells (34%), particularly multipotent progenitors (CFU-MIX, 12% of all cells). Four cytokine combinations were tested: (1) mast cell growth factor (MGF; a c-kit ligand) and interleukin-6 (IL-6); (2) MGF, IL-6, IL-3, and erythropoietin (Epo); (3) MGF, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF)/IL-3 fusion protein (FP), macrophage colony-stimulating factor (M-CSF), and granulocyte-CSF (G-CSF); and (4) MGF, IL-6, FP, M-CSF, G-CSF, and Epo. Maximum numbers of erythroid progenitors (BFU-E, up to 55-fold increase) and mature erythroid cells were observed in the presence of MGF, IL-6, IL-3, and Epo, whereas maximum levels of myeloid progenitors (CFU-C, up to 70-fold increase) and mature myeloid cells were found in cultures supplemented with MGF, IL-6, FP, M-CSF, and G-CSF. When MGF, IL-6, FP, M-CSF, G-CSF, and Epo were present, maximum levels of both erythroid and myeloid progenitors and their progeny were observed. These results indicate that specific cytokine combinations can act directly on primitive hematopoietic cells resulting in significant expansion of progenitor cell numbers and influencing their overall patterns of proliferation and differentiation. Furthermore, the observations presented in this study suggest that the cytokine combinations used were unable to bias lineage commitment of multipotent progenitors, but rather had a permissive effect on the development of lineage-restricted clonogenic cells. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO - ReferenceFenouille N et al. (DEC 2010) Cancer research 70 23 9659--70
Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
SPARC is an extracellular matrix protein that exerts pleiotropic effects on extracellular matrix organization, growth factor availability, cell adhesion, differentiation, and immunity in cancer. Chronic myelogenous leukemia (CML) cells resistant to the BCR-ABL inhibitor imatinib (IM-R cells) were found to overexpress SPARC mRNA. In this study, we show that imatinib triggers SPARC accumulation in a variety of tyrosine kinase inhibitor (TKI)-resistant CML cell lines. SPARC silencing in IM-R cells restored imatinib sensitivity, whereas enforced SPARC expression in imatinib-sensitive cells promoted viability as well as protection against imatinib-mediated apoptosis. Notably, we found that the protective effect of SPARC required intracellular retention inside cells. Accordingly, SPARC was not secreted into the culture medium of IM-R cells. Increased SPARC expression was intimately linked to persistent activation of the Fyn/ERK kinase signaling axis. Pharmacologic inhibition of this pathway or siRNA-mediated knockdown of Fyn kinase resensitized IM-R cells to imatinib. In support of our findings, increased levels of SPARC mRNA were documented in blood cells from CML patients after 1 year of imatinib therapy compared with initial diagnosis. Taken together, our results highlight an important role for the Fyn/ERK signaling pathway in imatinib-resistant cells that is driven by accumulation of intracellular SPARC. View PublicationCatalog #: Product Name: 04100 MethoCult™ H4100 Catalog #: 04100 Product Name: MethoCult™ H4100 - ReferenceLaurent B et al. (JAN 2010) Blood 115 3 687--95
High-mobility group protein HMGB2 regulates human erythroid differentiation through trans-activation of GFI1B transcription.
Gfi-1B is a transcriptional repressor that is crucial for erythroid differentiation: inactivation of the GFI1B gene in mice leads to embryonic death due to failure to produce differentiated red cells. Accordingly, GFI1B expression is tightly regulated during erythropoiesis, but the mechanisms involved in such regulation remain partially understood. We here identify HMGB2, a high-mobility group HMG protein, as a key regulator of GFI1B transcription. HMGB2 binds to the GFI1B promoter in vivo and up-regulates its trans-activation most likely by enhancing the binding of Oct-1 and, to a lesser extent, of GATA-1 and NF-Y to the GFI1B promoter. HMGB2 expression increases during erythroid differentiation concomitantly to the increase of GfI1B transcription. Importantly, knockdown of HMGB2 in immature hematopoietic progenitor cells leads to decreased Gfi-1B expression and impairs their erythroid differentiation. We propose that HMGB2 potentiates GATA-1-dependent transcription of GFI1B by Oct-1 and thereby controls erythroid differentiation. View PublicationCatalog #: Product Name: 04100 MethoCult™ H4100 04230 MethoCult™ H4230 09600 StemSpan™ SFEM Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 09600 Product Name: StemSpan™ SFEM - ReferenceFakler M et al. (FEB 2009) Blood 113 8 1710--22
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance.
Defects in apoptosis contribute to poor outcome in pediatric acute lymphoblastic leukemia (ALL), calling for novel strategies that counter apoptosis resistance. Here, we demonstrate for the first time that small molecule inhibitors of the antiapoptotic protein XIAP cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells. XIAP inhibitors at subtoxic concentrations, but not a structurally related control compound, synergize with TRAIL to trigger apoptosis and to inhibit clonogenic survival of acute leukemia cells, whereas they do not affect viability of normal peripheral blood lymphocytes, suggesting some tumor selectivity. Analysis of signaling pathways reveals that XIAP inhibitors enhance TRAIL-induced activation of caspases, loss of mitochondrial membrane potential, and cytochrome c release in a caspase-dependent manner, indicating that they promote a caspase-dependent feedback mitochondrial amplification loop. Of note, XIAP inhibitors even overcome Bcl-2-mediated resistance to TRAIL by enhancing Bcl-2 cleavage and Bak conformational change. Importantly, XIAP inhibitors kill leukemic blasts from children with ALL ex vivo and cooperate with TRAIL to induce apoptosis. In vivo, they significantly reduce leukemic burden in a mouse model of pediatric ALL engrafted in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Thus, XIAP inhibitors present a promising novel approach for apoptosis-based therapy of childhood ALL. View PublicationCatalog #: Product Name: 04100 MethoCult™ H4100 Catalog #: 04100 Product Name: MethoCult™ H4100 - ReferenceVormer TL et al. (DEC 2008) Molecular and cellular biology 28 24 7263--73
Anchorage-independent growth of pocket protein-deficient murine fibroblasts requires bypass of G2 arrest and can be accomplished by expression of TBX2.
Mouse embryonic fibroblasts (MEFs) deficient for pocket proteins (i.e., pRB/p107-, pRB/p130-, or pRB/p107/p130-deficient MEFs) have lost proper G(1) control and are refractory to Ras(V12)-induced senescence. However, pocket protein-deficient MEFs expressing Ras(V12) were unable to exhibit anchorage-independent growth or to form tumors in nude mice. We show that depending on the level of pocket proteins, loss of adhesion induces G(1) and G(2) arrest, which could be alleviated by overexpression of the TBX2 oncogene. TBX2-induced transformation occurred only in the absence of pocket proteins and could be attributed to downregulation of the p53/p21(CIP1) pathway. Our results show that a balance between the pocket protein and p53 pathways determines the level of transformation of MEFs by regulating cyclin-dependent kinase activities. Since transformation of human fibroblasts also requires ablation of both pathways, our results imply that the mechanisms underlying transformation of human and mouse cells are not as different as previously claimed. View PublicationCatalog #: Product Name: 04100 MethoCult™ H4100 Catalog #: 04100 Product Name: MethoCult™ H4100 - ReferenceMoulding DA et al. (SEP 2007) The Journal of experimental medicine 204 9 2213--24
Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia.
Specific mutations in the human gene encoding the Wiskott-Aldrich syndrome protein (WASp) that compromise normal auto-inhibition of WASp result in unregulated activation of the actin-related protein 2/3 complex and increased actin polymerizing activity. These activating mutations are associated with an X-linked form of neutropenia with an intrinsic failure of myelopoiesis and an increase in the incidence of cytogenetic abnormalities. To study the underlying mechanisms, active mutant WASp(I294T) was expressed by gene transfer. This caused enhanced and delocalized actin polymerization throughout the cell, decreased proliferation, and increased apoptosis. Cells became binucleated, suggesting a failure of cytokinesis, and micronuclei were formed, indicative of genomic instability. Live cell imaging demonstrated a delay in mitosis from prometaphase to anaphase and confirmed that multinucleation was a result of aborted cytokinesis. During mitosis, filamentous actin was abnormally localized around the spindle and chromosomes throughout their alignment and separation, and it accumulated within the cleavage furrow around the spindle midzone. These findings reveal a novel mechanism for inhibition of myelopoiesis through defective mitosis and cytokinesis due to hyperactivation and mislocalization of actin polymerization. View PublicationCatalog #: Product Name: 04100 MethoCult™ H4100 Catalog #: 04100 Product Name: MethoCult™ H4100 - ReferenceWunderlich M et al. (SEP 2006) Blood 108 5 1690--7
Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability.
The t(16:16) and inv(16) are associated with FAB M4Eo myeloid leukemias and result in fusion of the CBFB gene to the MYH11 gene (encoding smooth muscle myosin heavy chain [SMMHC]). Knockout of CBFbeta causes embryonic lethality due to lack of definitive hematopoiesis. Although knock-in of CBFB-MYH11 is not sufficient to cause disease, expression increases the incidence of leukemia when combined with cooperating events. Although mouse models are valuable tools in the study of leukemogenesis, little is known about the contribution of CBFbeta-SMMHC to human hematopoietic stem and progenitor cell self-renewal. We introduced the CBFbeta-MYH11 cDNA into human CD34+ cells via retroviral transduction. Transduced cells displayed an initial repression of progenitor activity but eventually dominated the culture, resulting in the proliferation of clonal populations for up to 7 months. Long-term cultures displayed a myelomonocytic morphology while retaining multilineage progenitor activity and engraftment in NOD/SCID-B2M-/- mice. Progenitor cells from long-term cultures showed altered expression of genes defining inv(16) identified in microarray studies of human patient samples. This system will be useful in examining the effects of CBFbeta-SMMHC on gene expression in the human preleukemic cell, in characterizing the effect of this oncogene on human stem cell biology, and in defining its contribution to the development of leukemia. View PublicationCatalog #: Product Name: 04100 MethoCult™ H4100 Catalog #: 04100 Product Name: MethoCult™ H4100 - ReferenceOnai N et al. (JAN 2006) The Journal of experimental medicine 203 1 227--38
Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development.
Flt3 ligand (Flt3L) is a nonredundant cytokine in type I interferon-producing cell (IPC) and dendritic cell (DC) development, and IPC and DC differentiation potential is confined to Flt3+ hematopoietic progenitor cells. Here, we show that overexpression of human Flt3 in Flt3- (Flt3(-)Lin(-)IL-7Ralpha(-)Thy1.1(-)c-Kit+) and Flt3+ (Flt3(+)Lin(-)IL-7Ralpha(-)Thy1.1(-)c-Kit+) hematopoietic progenitors rescues and enhances their IPC and DC differentiation potential, respectively. In defined hematopoietic cell populations, such as Flt3- megakaryocyte/erythrocyte-restricted progenitors (MEPs), enforced Flt3 signaling induces transcription of IPC, DC, and granulocyte/macrophage (GM) development-affiliated genes, including STAT3, PU.1, and G-/M-/GM-CSFR, and activates differentiation capacities to these lineages. Moreover, ectopic expression of Flt3 downstream transcription factors STAT3 or PU.1 in Flt3- MEPs evokes Flt3 receptor expression and instructs differentiation into IPCs, DCs, and myelomonocytic cells, whereas GATA-1 expression and consecutive megakaryocyte/erythrocyte development is suppressed. Based on these data, we propose a demand-regulated, cytokine-driven DC and IPC regeneration model, in which high Flt3L levels initiate a self-sustaining, Flt3-STAT3- and Flt3-PU.1-mediated IPC and DC differentiation program in Flt3+ hematopoietic progenitor cells. View PublicationCatalog #: Product Name: 04100 MethoCult™ H4100 Catalog #: 04100 Product Name: MethoCult™ H4100
10 Products
Shop By
Filter Results
- Resource Type
- Product Information Sheet 1 item
- Reference 17 items
- Technical Manual 1 item
- Product Type
- Cell Culture Media and Supplements 1 item
- Area of Interest
- Cancer 3 items
- Cord Blood Banking 1 item
- Drug Discovery and Toxicity Testing 2 items
- Immunology 1 item
- Stem Cell Biology 12 items
- Transplantation Research 2 items
- Brand
- EasySep 1 item
- MethoCult 18 items
- MyeloCult 1 item
- StemSpan 1 item
- Cell Type
- B Cells 2 items
- Dendritic Cells 1 item
- Hematopoietic Stem and Progenitor Cells 13 items
- Myeloid Cells 2 items
- T Cells 1 item